


Product Name : JH-RE-06
Cat. No. : PC-72501
CAS No. : 1361227-90-8
Molecular Formula : C₂₀H₁₆Cl₃N₃O₄
Molecular Weight : 468.72
Target : Other Targets
Solubility : 10 mM in DMSO



Biological Activity

JH-RE-06 is a potent REV1-REV7 interface inhibitor (IC₅₀=0.78 μM, K_d=0.42 μM) that disrupts mutagenic **translesion synthesis** (TLS) by preventing recruitment of mutagenic POLζ, induces REV1 dimerization and blocks POLζ recruitment. JH-RE-06 enhances cisplatin cytotoxicity and suppresses cisplatin-induced mutagenesis by interfering with REV1-dependent mutagenic TLS.

JH-RE-06 sensitizes cells to cisplatin and reduces HPRT mutations in a REV1-dependent manner.

JH-RE-06 (1.6 mg/kg, i.p.) improves tumor cell response to cisplatin in a xenograft mouse model.

JH-RE-06 is a novel TLS inhibitor as a class of chemotherapy adjuvants.

References

Wojtaszek JL, et al. Cell. 2019 Jun 27;178(1):152-159.e11.

Chatterjee N, et al. Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28918-28921.

Taglialatela A, et al. Mol Cell. 2021 Oct 7;81(19):4008-4025.e7.

Chen Y, et al. Cell Death Dis. 2022 Feb 3;13(2):110.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com